Matinas BioPharma Holdings, Inc. - MTNB Quarterly EPS earnings growth
The current quarterly EPS growth rate reflects the dynamics of Matinas BioPharma, whose strategy is based on converting complex injectable drugs into oral forms. Lipid nanocrystal technology provides molecule protection, allowing for flexible determination of licensing costs. Demand from pharma behemoths is expanding the client base, while the indicator has reached the level of 79.60.
%20Quarterly%20EPS%20earnings%20growth&width=1200&height=400&colorIndex=0&v=mwg3sw3k.w4s-7di3ke8&start=20220704&end=20261114&filename=GURU_Markets_-_MTNB_-_Matinas-BioPharma_-_Quarterly-EPS-earnings-growth "MTNB matinasbiopharma.com Quarterly EPS earnings growth (07/04/2022 - 11/14/2026) | 👁️GURU.Markets👁️")
Financial and market metric breakdowns for matinasbiopharma.com (MTNB)
- share price and consensus valuation forecast:
- issuer market value details:
- balance sheet net asset value indicators:
- debt and liquidity data:
Debt to Equity Matinas BioPharma|MTNB - Long-Term Debt to Equity|Short-Term Debt to Capital Matinas BioPharma|MTNB - Company Total Debt Obligations|Debt to Book Capitalization Ratio Matinas BioPharma Holdings, Inc.|MTNB - Long-Term Debt Volume|Company Short-Term Debt Matinas BioPharma|Quick Liquidity matinasbiopharma.com
- earnings and valuation multiples indicators:
MTNB - Net Income|Projected Future Earnings Matinas BioPharma|MTNB - P/E Multiple|Projected Price to Earnings matinasbiopharma.com|MTNB - Company Value to Earnings Growth Ratio|EV/EBITDA Multiple Matinas BioPharma Holdings, Inc.|MTNB - Operating income before deduction of amortization|Earnings per share for the last twelve months Matinas BioPharma|MTNB - Earnings per share for the last 12 months|Quarterly EPS earnings growth matinasbiopharma.com|MTNB - Earnings growth in current year|Net earnings per share growth forecast for next year Matinas BioPharma
- sales volume and revenue information:
Analysis of all company metrics:Matinas BioPharma
To minimize risks amid volatility, it is critical for investors to track net income per share, where the current quarterly EPS growth rate reflects the business's acceleration or deceleration vector. Growth in this metric confirms the effective scaling of software data automation and the implementation of robotic molecule screening stations for the LNC platform, transforming the technological progress of Matinas BioPharma (MTNB) into tangible financial results.
Competitors of Matinas BioPharma (MTNB)
ASND (Ascendis Pharma) - Year-over-year net earnings per share growth for the last 12 months|MDGL: Year-over-year earnings per share growth rate for the last twelve months|CORT (Corcept Therapeutics Corp) - Quarterly EPS earnings growth|Quarterly EPS earnings growth Rhythm Pharmaceuticals|Quarterly EPS earnings growth AKRO|Year-over-year earnings per share growth for the last twelve months MTSR (Metsera, Inc.)|Year-over-year earnings per share growth for the last twelve months moonlaketx.com MLTX|Crinetics Corp (CRNX) - Earnings per share growth in annualized terms for the last twelve months|NAMS - Year-over-year earnings per share growth for the last twelve months|SLNO: Year-over-year earnings per share growth for the last twelve months|FOLD: Quarterly EPS earnings growth|ETNB - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Agios Corp|Structure Corp (GPCR) - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months mimedx.com (MDXG)|Year-over-year net earnings per share growth for the last 12 months rezolutebio.com RZLT|Year-over-year earnings per share growth for the last twelve months Lexicon Pharmaceuticals, Inc. LXRX|MBX Bio - Year-over-year earnings per share growth for the last twelve months|ALT: Year-over-year net earnings per share growth for the last 12 months|AARD - Quarterly EPS earnings growth|SGMT: Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months BioAge Labs, Inc. (BIOA)|Year-over-year earnings per share growth for the last twelve months Biomea Fusion Inc|Year-over-year earnings per share growth for the last 12 months QNCX (Quince Therapeutics)|Year-over-year net earnings per share growth for the last 12 months GUTS (Fractyl Health)|Year-over-year earnings per share growth rate for the last twelve months VTVT|Agape ATP Corporation - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per one share growth for the last 12 months PLUR|Synlogic Inc. - Quarterly EPS earnings growth|LPCN (Lipocine) - Year-over-year earnings per share growth for the last 12 months|SPRB: Quarterly EPS earnings growth|Galecto Corp - Year-over-year earnings per one share growth for the last 12 months|CTCX (carmellrx.com) - Quarterly EPS earnings growth|Quarterly EPS earnings growth lumos-pharma.com|Quarterly EPS earnings growth ONVO|Year-over-year net earnings per share growth for the last 12 months Radius Health RDUS
